β-Arrestin 1 and 2 and G Protein-Coupled Receptor Kinase 2 Expression in Pituitary Adenomas: Role in the Regulation of Response to Somatostatin Analogue Treatment in Patients With Acromegaly
Open Access
- 1 December 2013
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 154 (12), 4715-4725
- https://doi.org/10.1210/en.2013-1672
Abstract
Recent in vitro studies highlighted G protein-coupled receptor kinase (GRK)2 and β-arrestins as important players in driving somatostatin receptor (SSTR) desensitization and trafficking. Our aim was to characterize GRK2 and β-arrestins expression in different pituitary adenomas and to investigate their potential role in the response to somatostatin analog (SSA) treatment in GH-secreting adenomas (GHomas). We evaluated mRNA expression of multiple SSTRs, GRK2, β-arrestin 1, and β-arrestin 2 in 41 pituitary adenomas (31 GHomas, 6 nonfunctioning [NFPAs], and 4 prolactinomas [PRLomas]). Within the GHomas group, mRNA data were correlated with the in vivo response to an acute octreotide test and with the GH-lowering effect of SSA in cultured primary cells. β-Arrestin 1 expression was low in all 3 adenoma histotypes. However, its expression was significantly lower in GHomas and PRLomas, compared with NFPAs (P < .01). GRK2 expression was higher in PRLomas and NFPAs compared with GHomas (P < .05). In the GHoma group, GRK2 expression was inversely correlated to β-arrestin 1 (P < .05) and positively correlated to β-arrestin 2 (P < .0001). SSA treatment did not affect GRK2 and β-arrestin expression in GHomas or in cultured rat pituitary tumor GH3 cells. Noteworthy, β-arrestin 1 was significantly lower (P < .05) in tumors responsive to octreotide treatment in vitro, whereas GRK2 and SSTR subtype 2 were significantly higher (P < .05). Likewise, β-arrestin 1 levels were inversely correlated with the in vivo response to acute octreotide test (P = .001), whereas GRK2 and SSTR subtype 2 expression were positively correlated (P < .05). In conclusion, for the first time, we characterized GRK2, β-arrestin 1, and β-arrestin 2 expression in a representative number of pituitary adenomas. β-Arrestin 1 and GRK2 seem to have a role in modulating GH secretion during SSA treatment.Keywords
This publication has 27 references indexed in Scilit:
- Novel pathway for somatostatin analogs in patients with acromegalyTrends in Endocrinology & Metabolism, 2013
- β-arrestin-mediated receptor trafficking and signal transductionTrends in Pharmacological Sciences, 2011
- Ligand-Dependent Mechanisms of sst2A Receptor Trafficking: Role of Site-Specific Phosphorylation and Receptor Activation in the Actions of Biased Somatostatin AgonistsMolecular Endocrinology, 2011
- Expression and Functional Analysis of Dopamine Receptor Subtype 2 and Somatostatin Receptor Subtypes in Canine Cushing’s DiseaseEndocrinology, 2008
- Differential β-Arrestin Trafficking and Endosomal Sorting of Somatostatin Receptor SubtypesPublished by Elsevier BV ,2004
- Mechanisms of regulation of the expression and function of G protein-coupled receptor kinasesCellular Signalling, 2003
- β‐Arrestin is involved in the desensitization but not in the internalization of the somatostatin receptor 2A expressed in CHO cellsFEBS Letters, 2002
- β-arrestin- and c-Src-dependent degradation of G-protein-coupled receptor kinase 2The EMBO Journal, 2001
- Differential Affinities of Visual Arrestin, βArrestin1, and βArrestin2 for G Protein-coupled Receptors Delineate Two Major Classes of ReceptorsPublished by Elsevier BV ,2000
- Selective Regulation of Endogenous G Protein-coupled Receptors by Arrestins in HEK293 CellsPublished by Elsevier BV ,2000